Use of c-Src inhibitors alone or in combinaton with STI571 for the treatment of leukaemia

Abstract

The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.

1 - 19 . (canceled)  
     
     
         20 . A method of treating a warm-blooded animal having leukemia comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in a quantity which is therapeutically effective against leukemia, alone or in combination with a Bcr-Abl inhibitor, wherein said leukemia is resistant to monotherapy employing N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine as sole active agent.  
     
     
         21 . The method according to  claim 20  wherein the at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, is administered alone.  
     
     
         22 . The method according to  claim 20  comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family.  
     
     
         23 . The method according to  claim 20  comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family.  
     
     
         24 . The method according to  claim 20  wherein said leukemia is chronic myelogenous leukemia.  
     
     
         25 . The method according to  claim 20  comprising administering to the animal at least one compound inhibiting the activity of a member of a kinase selected from src, yes, hck, fyn, lyn, lck, blk, fgr and Yrk.